- For a non-CTIMP (non-Clinical Trial of an Investigational Medicinal Product) you will need to make an amendment and send an email to hra.amendments@nhs.net
- For a CTIMP (Clinical Trial of an Investigational Medicinal Product) you will need to make a substantial amendment in IRAS.
For studies where the lead NHS R&D office is in Northern Ireland, Scotland or Wales amendments are categorised by the lead nation and shared across participating UK nations.
Guidance on submitting Amendments to projects involving the NHS/HSC is also available on IRAS help pages.
The guidance on this page does not apply to:
- Research Tissue Banks (RTB) and Research Databases (RDB) as these do not need HRA Approval;
- Urgent Safety Measures. These should be sent to all participating organisations on receipt to ensure the participants' safety. Subsequent notifications, including resulting amendments should be submitted, as appropriate and according to relevant guidance; or
- Notifications of the end of a study. These are not amendments and should be notified to the REC using the appropriate Notice of End of Study form.